A Randomized, Placebo-controlled, Double-blinded Study With GB-0998 for Unexplained Primary Recurrent Miscarriage

Trial Profile

A Randomized, Placebo-controlled, Double-blinded Study With GB-0998 for Unexplained Primary Recurrent Miscarriage

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Immunoglobulin G (Primary)
  • Indications Spontaneous abortion
  • Focus Registrational; Therapeutic Use
  • Sponsors Japan Blood Products Organization
  • Most Recent Events

    • 06 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
    • 06 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.
    • 24 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top